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lymphoid-specific and inducible enhancer element
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ABSTRACT The immunoglobulin K light chain gene con-
tains a lymphoid-specific enhancer that includes several short
protein-binding sequences. The sequence that binds the nu-
clear factor NF-KB was tested for its ability to act indepen-
dently as an enhancer element by inserting it into test plasmids
containing the chloramphenicol acetyltransferase gene. When
analyzed for activity by transient transfection into lymphoid
and nonlymphoid cells, a single copy of the NF-#cB binding site
could act as a tissue-specific upstream activating element. Two
copies (dimer) showed 10-fold higher activity than did one
copy and could act as an enhancer element 2.5 kilobases
downstream of the transcriptional start site. The enhancer
activity of this sequence was correlated with the presence of
the cognate binding protein, NF-KB. This sequence acted as an
inducible enhancer under conditions that induce NF-cB bind-
ing activity. Thus, the NF-#cB binding site acts by itself as a
tissue-specific and inducible enhancer element, and two copies
show cooperative interaction.
The specific expression of immunoglobulin K light chain
genes in mature B cells is regulated by multiple sequences
within the promoter and enhancer regions (1-3). The lym-
phoid-specific enhancer of the K light chain gene contains
several short sequence elements that bind trans-acting fac-
tors (4). Within the enhancer, there are three copies of a
sequence homologous to the consensus sequence CAGGTG-
GC, or E motif, originally described by Ephrussi et al. (5) as
protein binding sites in the immunoglobulin heavy chain
enhancer. In addition, the K light chain gene enhancer ("K
enhancer") contains the sequence GGGACTTTCC, called
the B or KB site, which binds the nuclear factor NF-KB (4).
Each of these sites has been shown by mutational analysis to
be important to the functional activity of the K enhancer (6).
Clustered mutations in the KB site completely abolish en-
hancer function identifying this site as crucial to K enhancer
activity.
The DNA-binding protein NF-KB is found constitutively
only in mature B cells that transcribe-K light chain genes. In
pre-B-cells stimulated with lipopolysaccharide (LPS), the
activation of K light chain gene transcription is correlated
with an induction of the NF-KB DNA binding activity by a
posttranslational mechanism (7). Thus, the NF-KB protein is
important in the activation of K light chain gene transcription
during B-lymphocyte development.
Interestingly, NF-KB plays a role in the activation of other
genes as well. NF-KB binding sequences are found in the
human immunodeficiency virus (HIV) enhancer (8, 9); the
simian virus 40 (SV40) enhancer (10), and the cytomegalo-
virus enhancer (11) and upstream of major histocompatibility
complex class I genes (12, 13). The NF-KB DNA-binding
protein can be induced in T cells or HeLa cells by treatment
with phorbol ester (7). In the case of the HIV enhancer,
which is activated in T cells, two tandem copies of the
NF-KB binding site are present in the long terminal repeat
region. Mutation of these NF-KB binding sequences pre-
vents the activation of the HIV enhancer in T cells stimu-
lated with phorbol 12-myristate 13-acetate (PMA) and phy-
tohemagglutinin (PHA) (9). This suggests that the nuclear
factor NF-KB is important to the activation of the HIV
enhancer in T cells. The possible role of NF-KB in regulating
gene expression in nonlymphoid cells has not been estab-
lished.
To better understand the mechanism of tissue-specific
enhancer activity, we tested whether the NF-KB binding site
could act independently as an enhancer element. We found
that a single copy of the KB site acts as an invertible
upstream activating element. Dimers of the KB site show
10-fold higher activity and function as an enhancer element
2.5 kilobases (kb) downstream of the start of transcription.
The enhancer activity of the KB-containing oligonucleotide
was highest in mature B cells but could be induced in
pre-B-cells treated with LPS or in T cells treated with PMA
and PHA. We conclude that the sequence that binds NF-KB
can act by itself as a tissue-specific and inducible enhancer
element.
MATERIALS AND METHODS
Plasmid Constructions. Plasmids were derived from the
A-71-c-fos-CAT plasmids described by Gilman et al. (14).
This plasmid was modified by inserting an Xho I linker at the
unique Nde I site located 2.5 kb downstream of the mRNA
cap site. Synthetic oligonucleotides containing the KB se-
quence or a related sequence (Fig. 1) were synthesized on an
Applied Biosystems (Foster City, CA) 380A DNA synthe-
sizer by Susan Blackmon (Whitehead Institute, Oligonucle-
otide Synthesis Facility, Cambridge, MA). For cloning,
complementary oligonucleotides were treated with kinase,
hybridized, and inserted at either the Sal I site at position
- 71 or the Xho I site 2.5 kb downstream as indicated in the
text. The total size of the plasmids was 5.1 kb.
Cell Culture, Transfections, and Enzymatic Assays. My-
eloma cells (S194), pre-B-cells (38B9), or T cells (Jurkat)
were maintained in RPMI 1640 medium containing 10%
(vol/vol) fetal calf serum and 50 ,uM 2-mercaptoethanol.
Transfections of lymphoid cells were performed by the
DEAE-dextran technique (16) as modified by Grosschedl
and Baltimore (17) with 10 ,g of test plasmid for 2 x 107
cells. 38B9 cells were induced with Bacto LPS (Salmonella
typhosa 0901; Difco) at 10 ,ug/ml for 40 hr. Twenty-four
hours after transfection, Jurkat cells were induced with PHA
Abbreviations: CAT, chloramphenicol acetyltransferase; LPS, lipo-
polysaccharide; PMA, phorbol 12-myristate 13-acetate; PHA, phy-
tohemagglutinin; HIV, human immunodeficiency virus; SV40, sim-
ian virus 40; K enhancer, K light chain gene enhancer.
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A
000
TCGACAGAGGGACTTTCC AGAGGC
GTCT CCTGAAAG TCTCCGAGCT
B
TCGACAG CCTTTC AGAGGC
GTCT Gf GAAAGG TCTCCGAGCT
FIG. 1. Synthetic oligonucleotides. (A) KB-containing oligonu-
cleotide. The sequence corresponds to that found in the immuno-
globulin K light chain gene intron (positions 3937-3958) (15) with Sal
I- and Xho I-compatible ends. The arrow indicates the 5'-to-3'
orientation in the K light chain gene. Filled circles indicate the
guanosine residues whose methylation interferes with NF-KB bind-
ing in vitro (4). (B) Mutant oligonucleotide. The sequence within the
box indicates nucleotides that were altered from the sequence in A
to eliminate residues important for NF-KB binding.
(ICN Immunobiologicals, Lisle, IL) at 2 ,tg/ml and PMA
(Sigma) at 50 ng/ml for 18 hr. Lysates from lymphoid cells
were prepared 40-44 hr after transfection and treated for 7
min at 60'C to inactivate an endogenous deacetylase activ-
ity. Chloramphenicol acetyltransferase (CAT) assays were
performed by the procedure of Gorman et al. (18) with 100
,ug of protein for each determination. The percentage of
chloramphenicol that was acetylated was determined by
cutting out regions containing unreacted [14C]chloram-
phenicol (New England Nuclear) and acetylated forms and
quantitating the amount of radioactivity by liquid scintilla-
tion counting.
BALB/c 3T3 or HeLa cells were grown in Dulbecco's
modified Eagle's medium with 10% calf serum and transfect-
ed by the calcium phosphate coprecipitation procedure (19,
20). A mixture of 10 ,ug of the test plasmid and 5 ,ug of Rous
sarcoma virus-conjugated B-galactosidase gene (RSV-,3gal)
was transfected for each experiment. After 48 hr cell lysates
were prepared, and 100 ,ug of protein was assayed for both
CAT activity and f3-galactosidase activity. The fB-galacto-
sidase levels were assayed as described (21) and used to
normalize transfection efficiency.
Relative CAT activities were determined by averaging two
or more independent experiments and comparing them to a
basal level of activity with the control plasmid, A-71-c-fos-
CAT, which contains no enhancer element. The values in the
right column of Fig. 2 (relative CAT activity in 3T3 lysates)
were calculated after normalizing each separate assay rela-
tive to the f3-galactosidase activity. The standard deviation
for relative CAT values was <20%o for assays of lymphoid
lysates and <30% for assays of 3T3 or HeLa lysates.
RESULTS
NF-#cB Binding Oligonucleotide Can Function as an En-
hancer Element. Enhancer elements have been defined as
regulatory sequences that activate transcription of a linked
gene, can function in either orientation, and can act at a
distance. To determine whether a short oligonucleotide
containing the KB sequence could act independently as an
enhancer element, we constructed a synthetic 26-base-pair
(bp) oligonucleotide including 22 bp from the K enhancer
with Xho I- and Sal I-compatible ends for cloning (see Fig.
1A). This oligonucleotide was shown to bind the nuclear
factor NF-KB by using an electrophoretic mobility shift
assay (M.L., unpublished data).
To test this oligonucleotide for enhancer properties, we
inserted it into a test plasmid lacking an enhancer. The test
plasmid contained a truncated c-fos promoter linked to the
CAT gene. The c-fos promoter included only 71 bp upstream
from the transcription start site, including one strong pro-
moter element but lacking serum- or PMA-inducible ele-
ments (14). This promoter was chosen because it is active in
a variety of cell types. The function of the KB-containing
oligonucleotide was assayed by inserting one or two copies
at the 5' end of the truncated promoter or 2.5 kb downstream
(Fig. 2). Test plasmids were transfected into the myeloma
cell line S194, and transient expression of the CAT enzyme
was used as a measure of transcriptional activity. Because
the inserted oligonucleotide did not interrupt the transcribed
region, differences in CAT activity were assumed to reflect
differences in the rate of transcription.
The control plasmid containing the c-fos promoter with no
inserted enhancer gave a background of -0.12% conversion
of chloramphenicol to its acetylated forms. Activity of
plasmids containing inserts was compared to this basal level
to give relative CAT activity. A single copy of the 26-bp
oligonucleotide inserted at position - 71 activated CAT
levels about 20-fold in S194 cells (Fig. 2, lines 2 and 3). The
c-FOS CAT
SAL I XHO I
-71 +2.5kb
2
3
4 - e l 11
IY I .11.III-
54---
5 ~ ~ ~
----I1
6
7
8
wf ~~~~~~~~1
4-
9=
10 ' ' wv
114- g w
i11 _ _ _ I- i~ z
RELATIVE CAT
ACTIVITY
S194 3T3
1 1
24
19
324
235
1.5
1.5
42
50
32
28
3.1
3.9
9.5*
n.d.
n.d.
n.d.
6.4
3.3
n.d.
n.d.2
FIG. 2. Relative CAT activities directed by transfected c-fos-
CAT plasmids with inserted KB sites. Transfections and enzyme
assays were carried out as described in text. Line 1 represents the
A-71-c-fos-CAT plasmid containing no insert. The thin arrow indi-
cates the transcriptional start site within the c-fos promoter. Lines
2-11 represent A-71-c-fos-CAT plasmids containing inserted KB-
containing oligonucleotides. Bold arrows indicate positions and
orientations of the inserted KB sites shown in Fig. 1. Relative CAT
activity is the average of at least two independent transfections
except where noted with an asterisk, which indicates that only one
experiment was performed. n.d., Not determined.
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KB sequence functioned at approximately equal levels in
either orientation. Interestingly, when two copies of the
oligonucleotide were inserted at this position, the resulting
plasmids showed a 200- to 300-fold increase in CAT activity
relative to the plasmid with no enhancer (Fig. 2, lines 4 and
5). High levels ofCAT activity were seen when dimers were
oriented as inverted or direct repeats. The activity was much
greater than would be expected if the effects of the two
oligonucleotides were additive. This suggests that adjacent
KB sites collaborate to give a high level of transcriptional
activation. The spacing of the NF-KB binding nucleotides in
these constructs can be deduced from previous methylation
interference experiments on fragments containing this se-
quence (4). The guanosine residues that are important for
binding (see Fig. 1A) are spaced 18 bp apart in the inverted
repeat construct (Fig. 2, line 4) and 16 bp apart in the direct
repeat construct (Fig. 2, line 5). A high level of transcription
was achieved with either spacing.
When a single copy of the KB site was inserted at a
position 2.5 kb downstream of the start of transcription, it
had little or no effect on the level of CAT activity (Fig. 2,
lines 6 and 7). By contrast, two copies of the oligonucleotide
inserted at this site gave a 40- to 50-fold enhancement of
CAT activity (Fig. 2, lines 8 and 9). The level of enhancer
activity with two KB sites, as either direct or inverted
repeats, was about the same as that observed for the intact K
enhancer. Plasmids containing one KB site at position -71
and another at a position 2.5 kb downstream gave levels of
CAT activity that were not significantly different from that
seen with plasmids containing only one copy of the KB site at
the -71 position (Fig. 2, lines 10 and 11). Therefore, the
presence of two widely separated KB sites is not sufficient to
generate the high level of transcription seen with adjacent
sites. We have not yet determined the precise spacing
requirements for the functional interaction of NF-KB binding
sites.
KB Site Acts as a Tissue-Specific Enhancer. To determine
whether the NF-KB binding oligonucleotide acts in a tissue-
specific manner, plasmids containing the KB site were tested
in a variety of cell types. In BALB/c 3T3 cells, such plasmids
showed a significant increase in CAT activity when com-
pared with the plasmid containing no enhancer (Fig. 2, right
column). Thus, in these cells, the KB site activates CAT
transcription but to a much lower degree than in mature B
cells. We also tested the constructs containing two KB sites
(Fig. 2, lines 8 and 9) in HeLa cells, pre-B-cells (38B9), and
T cells (Jurkat). In these cell types, we observed no signifi-
cant increase in CAT activity compared to plasmids lacking
any enhancer (data not shown). The inactivity of the oligo-
nucleotide in these cell types parallels the tissue specificity
of the intact K enhancer. The measurable enhancer activity
of the synthetic oligonucleotide in 3T3 cells remains to be
explained.
KB Site Acts as an Inducible Enhancer. To study the role of
NF-KB binding sequences in the activation of the K light
chain gene at an earlier stage of B-cell development, we
assayed the ability of this sequence to function as an
inducible enhancer in tumor pre-B-cells. Test plasmids con-
taining two copies of the KB site were transfected into the
pre-B-cell line 38B9. The intact K enhancer is inducible with
LPS in these cells (see below). Induction experiments were
carried out in this cell line and not the more extensively
studied 70Z/3 cell line (7) because transfection efficiency
was significantly higher for 38B9 cells. The c-fos-CAT
plasmid containing no enhancer and a plasmid containing the
entire K enhancer (470-bp Alu I fragment) (6) also were
tested. The plasmid containing no enhancer gave the same
CAT activity in LPS-treated or untreated cells (Table 1). The
K enhancer conferred 30-fold inducibility to the CAT gene.
Similarly, plasmids containing two copies of the KB site at
Table 1. KB site acts as an LPS-inducible element in 38B9
pre-B-cells
% conversion
Test plasmid - LPS + LPS
A-71-c-fos-CAT <0.1 <0.1
K-CAT 0.24 7.3
(KB)2-CAT 0.25 9.6
The values represent absolute % conversion of [14C]chloramphen-
icol to its acetylated forms. K-CAT plasmid includes the 470-bp Alu
I fragment containing the K enhancer. (KB)2-CAT plasmid includes
two copies of the KB-containing oligonucleotide inserted at position
-71 as shown in line 4 of Fig. 2.
the -71 position gave a 38-fold induction upon LPS treat-
ment. Constructs containing one copy of the KB site at the
- 71 position or two copies at 2.5 kb downstream gave 4- to
6-fold induction in LPS-treated 38B9 cells (data not shown).
These results suggest that the KB site acts by itself as an
LPS-inducible enhancer element in pre-B-cells, and two
copies have an activity as powerful as the entire K enhancer.
To examine the function of NF-KB binding sequences in
the activation of genes in non-B-cells, we tested the ability of
this sequence to act as an inducible enhancer element in T
cells (Jurkat). Previous studies have shown that the NF-KB
DNA binding protein is inducible in this cell type upon
treatment with PMA and PHA (7, 9). Test plasmids contain-
ing no enhancer, the HIV enhancer (22), the intact K en-
hancer, or two KB sites were transfected separately into
Jurkat cells. Half of each population was treated with PMA
at 50 ng/ml and PHA at 2 tug/ml for 18 hr. The HIV-CAT
plasmid, which contains the HIV long terminal repeat with
both enhancer and promoter elements, showed about a
30-fold induction (Fig. 3, lanes 2 and 3) as has been observed
previously (9). The construct with two KB sites inserted in
the c-fos-CAT plasmid at position -71 (see Fig. 2, line 4)
showed a dramatic 180-fold induction (Fig. 3, lanes 6 and 7).
Inducible CAT activity also was observed with plasmids
containing a single copy of the KB site at position - 71 or two
KB sites at 2.5 kb downstream (data not shown). These
results suggest that the NF-KB binding sequence acts inde-
pendently as a PMA-inducible enhancer element in T cells.
Interestingly, the K enhancer (470-bp fragment), which con-
tains one KB site and three consensus E motifs, did not
confer inducibility to the CAT gene upon activation of T
cells (Fig. 3, lanes 4 and 5). This marked lack of inducibility
may reflect negative regulation of the K enhancer in T cells.
A Mutant KB Site Has No Enhancer Activity. To be certain
that the enhancer activity of the 26-bp oligonucleotide was
due to sequences that bind NF-KB, we constructed a mutant
oligonucleotide lacking NF-KB binding activity. In this oli-
gonucleotide (Fig. 1B), three nucleotides that were previ-
ously shown to be important for NF-KB binding were altered
(7). This altered sequence did not compete with the wild-
type sequence for binding of NF-KB in an electrophoretic
mobility shift assay (data not shown). Two copies of the
mutant oligonucleotide were inserted as inverted repeats at
the Xho I site in c-fos-CAT plasmids to create a configura-
tion identical to that on line 9 in Fig. 2. The plasmid
containing mutant oligonucleotides was tested for enhancer
activity in S194 cells and compared to the analogous plasmid
containing NF-KB binding sequences (Fig. 4). Whereas
oligonucleotides that bound NF-KB enhanced transcription
of the CAT gene, the mutant oligonucleotides had no effect
on the level ofCAT activity when compared to the construct
lacking an enhancer. Thus, the specific sequences that are
required for NF-KB binding are required for the enhancer
function of the 26-bp oligonucleotide.
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j_ FIG. 3. CAT analysis of Jurkat cells transfect-
AC ed with HIV-CAT, K-CAT, or (KB)2-CAT plas-
mids. Jurkat cells were transfected by the DEAE-
dextran procedure, and CAT analysis was per-
formed as described in text. Induction with PMA
(50 ng/ml) and PHA (2 gg/ml) was carried out on
halfof the transfected populations (+ lanes) for 18
C hr. Lanes: 1, mock transfected; 2 and 3, HIV-CAT(22); 4 and 5, K-CAT plasmid, which includes a
470-bp Alu I fragment from the K enhancer in-
serted at the Sal I site at - 71 in c-fos-CAT; 6 and
7, (KB)2-CAT plasmid including two KB sites in-
serted at - 71 in c-fos-CAT as shown in line 4 of
Fig. 2. Results of induction with PMA and PHA
are shown in lanes 3, 5, and 7. The bracket marked
"C" indicates unreacted substrate [14C]chloram-
phenicol; the bracket marked "Ac" indicates
acetylated forms.
DISCUSSION
We have shown that a short NF-KB binding sequence can act
as an enhancer element independent of other motifs in the K
enhancer. As found for the entire enhancer, this sequence
confers tissue specificity and inducibility to a linked gene.
Monomers of this site activated transcription when posi-
tioned closely upstream of the TATA box but had no
detectable function at a 2.5-kb distance downstream. By
contrast, dimers of the NF-KB binding site were -10-fold
more active than monomers and showed activity at a dis-
tance.
In its natural context in the K enhancer, a single copy of
the KB site is found together with three consensus E motifs.
Mutation of the KB site abolishes the activity of the enhancer
(6), identifying it as a crucial enhancer element. The ability
of this site to act independently of others suggests that the E
motifs are not necessary to enhancer function, although both
1 2 3 4
MOCK NO (KB)2
ENHANCER
(MUTANT-KB) 2
FIG. 4. Effect of mutation of the KB site on the enhancer activity
of the synthetic oligonucleotide. S194 myeloma cells were transfect-
ed by the DEAE-dextran procedure, and extracts were assayed for
CAT activity as indicated in text. Extracts were from untransfected
cells (lane 1), cells transfected with A-71-c-fos-CAT plasmid (no
enhancer) (lane 2), cells transfected with A-71-c-fos-CAT with two
KB sites inserted as inverted repeats at 2.5 kb from the transcrip-
tional start site as shown in Fig. 2, line 9 (lane 3), and cells
transfected with A-71-c-fos-CAT with two mutant KB sites (see Fig.
1B) inserted as inverted repeats at 2.5 kb from the transcriptional
start site (lane 4).
mutational studies (6) and our present data show that the E
motifs contribute to enhancer activity. This contribution is
evident when the activity of the KB site is compared to that
of the entire K enhancer in the downstream position. A single
KB site by itself is not sufficient for enhancer activity at a
distance. However, two copies of the KB site are as active as
the entire enhancer.
Our observation that dimers of the KB site enhance tran-
scription of a linked gene 10-fold better than a monomer does
is consistent with previous results on the oligomerization of
short protein-binding segments from other enhancers. Gerster
et al. (23) showed that a fragment from the immunoglobulin
heavy chain gene enhancer containing an "octamer" motif
and an E motif ("footprint" region) functions as a lymphoid-
specific enhancer when multimerized but also showed that a
single copy had only a marginal effect on transcription. In
addition, multimers of short protein-binding sequences from
the SV40 enhancer have been shown to act as cell type-
specific enhancer elements (24, 25). It is interesting to com-
pare our results to those of Schirm et al. (24) and Ondek et al.
(25) on the oligomerization of an SV40 element that includes
an NF-KB binding site. Multimers of the "core C" element
from SV40, containing a KB site and the core consensus
sequence TGGAAAG, gave enhancer activity in many lym-
phoid and nonlymphoid cell lines. This activity could be due
to proteins binding at the KB site, the SV40 core, or other
sequences in this region. Our oligonucleotide from the K
enhancer showed preferential activity in mature B cells. We
showed by analysis of a mutant oligonucleotide that the
NF-KB binding site is the only sequence within our 26-bp
oligonucleotide that functions as an enhancer. Thus, the
NF-KB binding site by itself acts in a lymphoid-specific
fashion but, when combined with an overlapping element
such as the SV40 core consensus, the resulting composite
sequence is active in many cell types. Unique patterns of
tissue-specific or stage-specific gene expression appear to be
achieved through the combinatorial effects of different trans-
acting factors, each having a distinct activity.
We observed a synergistic activity of adjacent KB sites.
This may be the result of cooperative binding of NF-KB
protein to the duplicated sites on the DNA or to a more
productive interaction of the bound NF-KB protein with other
proteins of the transcriptional apparatus. In the context of the
SV40, HIV, or cytomegalovirus enhancers, the KB site natu-
rally occurs in two or more copies, and this may account for
the high activity of these enhancers in certain cell types.
Interestingly, we found that the NF-KB binding sequence
activates transcription in non-B-cells. In Jurkat cells induced
MOCK
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with phorbol esters, activity is probably due to a protein that
is similar or identical to the NF-KB found in B cells as
defined by binding assays (7, 9). The low level of enhancer
activity in 3T3 cells may be due to a low and previously
undetected level ofNF-KB protein or to some related protein
that binds this sequence. A candidate for this protein is the
nuclear factor, H2TF1, described by Baldwin and Sharp
(13), which is present in 3T3 cells and has been reported to
interact at a low level with the KB site from the K enhancer
(26). This factor may be responsible for the activity of the
NF-KB binding oligonucleotide in 3T3 cells. In all other cell
types examined, we found a complete correlation between
the activity of the KB site and the presence of the NF-KB
factor. Thus, the binding of a short oligonucleotide to a
single nuclear factor, NF-KB, accounts for most of the
properties of the intact K enhancer, including lymphoid-
specificity and developmental activation during B-cell ontog-
eny.
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